Markus J. Lehtinen

Markus J. Lehtinen

Auto-generated profile, based on publicly available information

Markus J. Lehtinen

Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MLMarkus J. Lehtinen
Markus J. Lehtinen
ARAngelique L. Rops
Angelique L. Rops
DIDavid E. Isenman
David E. Isenman
JVJohan van der Vlag
Johan van der Vlag
TJT. Sakari Jokiranta
T. Sakari Jokiranta
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy associated with mutations in complement proteins, most frequently in the main plasma alternative pathway regulator factor H (FH). The hotspot for the FH mutations is in domains 19-20 (FH19-20) that are indispensable for FH activity on C3b bound covalently to host cells. In aHUS, down-regulation of cell-bound C3b by FH is impaired, but it is not clear whether this is due to an altered FH binding to surface-bound C3b or to cell surface structures. To explore the molecular pathogenesis of aHUS we tested binding of 14 FH19-20 point mutants to C3b and its C3d fragment, mouse glomerular endothelial cells (mGEnC-1), and heparin. The cell binding correlated well, but not fully, with heparin binding and the cell binding site was overlapping but distinct from the C3b/C3d binding site that was shown to extend to domain 19. Our results show that aHUS-associated FH19-20 mutants have different combinations of three primary defects: impaired binding to C3b/C3d, impaired binding to the mGEnC-1 cells/heparin, and, as a novel observation, an enhanced mGEnC-1 cell or heparin binding. We propose a model of the molecular pathogenesis of aHUS where all three mechanisms lead eventually to impaired control of C3b on the endothelial cell surfaces. Based on the results with the aHUS patient mutants and the overlap in FH19-20 binding sites for mGEnC-1/heparin and C3b/C3d we conclude that binding of FH19-20 to C3b/C3d is essential for target discrimination by the alternative pathway.

1 December 2004 in Journal of Molecular Biology
Verified
Journal Article
Closed access
MLMarkus J. Lehtinen
Markus J. Lehtinen
SMSeppo K Meri
Seppo K Meri
TJT. Sakari Jokiranta
T. Sakari Jokiranta

30 September 2009 in Molecular Immunology
Verified
Journal Article
Closed access
HSHannah Söderholm
Hannah Söderholm
MLMarkus J. Lehtinen
Markus J. Lehtinen
AKAino Koskinen
Aino Koskinen
TJT. Sakari Jokiranta
T. Sakari Jokiranta

31 August 2010 in Molecular Immunology
Verified
Journal Article
Closed access
HAHanne Amdahl
Hanne Amdahl
IJIlse Jongerius
Ilse Jongerius
TPTanja Pasanen
Tanja Pasanen
MLMarkus J. Lehtinen
Markus J. Lehtinen
JSJos A.G. van Strijp
Jos A.G. van Strijp
TJT. Sakari Jokiranta
T. Sakari Jokiranta

31 August 2010 in Molecular Immunology
Verified
Journal Article
Closed access
TKTommi Kajander
Tommi Kajander
ABArnab Bhattacharjee
Arnab Bhattacharjee
MLMarkus J. Lehtinen
Markus J. Lehtinen
SHSatu Hyvärinen
Satu Hyvärinen
ELElisa Leung
Elisa Leung
TJT. Sakari Jokiranta
T. Sakari Jokiranta

31 August 2010 in Molecular Immunology
Verified
Journal Article
Closed access
HSHarald Seeberger
Harald Seeberger
SSStefanie Strobel
Stefanie Strobel
MLMarkus J. Lehtinen
Markus J. Lehtinen
TJT. Sakari Jokiranta
T. Sakari Jokiranta
MJMihály Józsi
Mihály Józsi